Yuzhou Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yuzhou Chang has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Rui-Chao Chai
Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
3 shared publications - Bo Pang
Department of Brain Tumor Research Center, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University , Beijing
2 shared publications Hao Yan
Department of Brain Tumor Research Center, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University , Beijing
2 shared publications- Tao Jiang
Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
2 shared publications - Zheng Zhao
Beijing Neurosurgical Institute, Capital Medical University, Beijing, China
2 shared publications - Aden Ka-Yin Chan
Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, China
1 shared publication
Latest Publications
- 28 September 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
H3K27me3 loss and METTL3-m6A converge to upregulate SOX11/SMARCA4 and drive H3K27-altered spinal cord glioma stemness and proliferation
Background: H3 K27-altered diffuse midline gliomas (H3-DMGs) are driven by stem-like and proliferative tumor cells resulting from global H3K27me3 loss. Here, we aimed to identify key molecular mechanisms involved in the interplay between epigenetic and epitranscriptomic regulation underlying this process. Methods: Patient-derived spinal cord H3-DMG stem-like spheres and serum-induced differentiated cells were used to model tumor plasticity. Multi-omics approaches, including single-cell RNA sequencing, spatial transcriptomics, RNA m6A profiling, CUT&Tag, ATAC-seq, and in vitro and in vivo assays were performed to dissect epigenetic and epitranscriptomic regulation of stemness. Results: Differentiation reduced stemness markers, proliferation, H3K27M expression, and global m6A levels, while increasing H3K27me3. METTL3 was significantly downregulated during differentiation and positively correlated with stemness and proliferation in patient tumors. METTL3 promoted tumor stemness and growth by stabilizing SOX11 mRNA through YTHDC2-dependent m6A recognition. In parallel, H3K27me3 loss relieved transcriptional repression at both METTL3 and SOX11 loci, leading to SOX11 overexpression. Functionally, SOX11 interacted with SMARCA4, the core ATPase of the SWI/SNF complex, to enhance chromatin accessibility and activate stemness-associated transcriptional programs marked by H3K27ac and H3K4me3 enrichment. Clinically, METTL3 and SOX11 were upregulated in H3K27M-mutant tumors, and high SOX11 expression correlated with increased proliferation, poor prognosis, and enhanced sensitivity to the SMARCA4 inhibitor BRM014. Conclusions: H3K27M-driven epigenetic dysregulation promotes SOX11 overexpression through combined H3K27me3 loss and METTL3-mediated m6A modification. SOX11 sustains tumor stemness and proliferation by recruiting SMARCA4 to remodel chromatin and serves as both a prognostic biomarker and a predictor of response to SMARCA4-targeted therapy in spinal cord H3-DMG.
- 28 September 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
H3K27me3 loss and METTL3-m6A converge to upregulate SOX11/SMARCA4 and drive H3K27-altered spinal cord glioma stemness and proliferation
Background: H3 K27-altered diffuse midline gliomas (H3-DMGs) are driven by stem-like and proliferative tumor cells resulting from global H3K27me3 loss. Here, we aimed to identify key molecular mechanisms involved in the interplay between epigenetic and epitranscriptomic regulation underlying this process. Methods: Patient-derived spinal cord H3-DMG stem-like spheres and serum-induced differentiated cells were used to model tumor plasticity. Multi-omics approaches, including single-cell RNA sequencing, spatial transcriptomics, RNA m6A profiling, CUT&Tag, ATAC-seq, and in vitro and in vivo assays were performed to dissect epigenetic and epitranscriptomic regulation of stemness. Results: Differentiation reduced stemness markers, proliferation, H3K27M expression, and global m6A levels, while increasing H3K27me3. METTL3 was significantly downregulated during differentiation and positively correlated with stemness and proliferation in patient tumors. METTL3 promoted tumor stemness and growth by stabilizing SOX11 mRNA through YTHDC2-dependent m6A recognition. In parallel, H3K27me3 loss relieved transcriptional repression at both METTL3 and SOX11 loci, leading to SOX11 overexpression. Functionally, SOX11 interacted with SMARCA4, the core ATPase of the SWI/SNF complex, to enhance chromatin accessibility and activate stemness-associated transcriptional programs marked by H3K27ac and H3K4me3 enrichment. Clinically, METTL3 and SOX11 were upregulated in H3K27M-mutant tumors, and high SOX11 expression correlated with increased proliferation, poor prognosis, and enhanced sensitivity to the SMARCA4 inhibitor BRM014. Conclusions: H3K27M-driven epigenetic dysregulation promotes SOX11 overexpression through combined H3K27me3 loss and METTL3-mediated m6A modification. SOX11 sustains tumor stemness and proliferation by recruiting SMARCA4 to remodel chromatin and serves as both a prognostic biomarker and a predictor of response to SMARCA4-targeted therapy in spinal cord H3-DMG.
- Open Access
- 18 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (16) , eadu3956
Ara-C suppresses H3 K27–altered spinal cord diffuse midline glioma growth and enhances immune checkpoint blockade sensitivity
H3 K27–altered spinal cord diffuse midline glioma (H3-SCDMG) poses therapeutic challenges. Analysis of 73 clinical samples revealed heightened proliferation in H3-SCDMG versus wild-type tumors, suggesting therapeutic vulnerabilities. Drug screening identified cytarabine (Ara-C) as highly effective in inhibiting proliferation in H3 K27M cell models, recently established patient-derived cells, and patient-derived xenograft models. Mechanistically, Ara-C can suppress tumor growth through DNA damage, cell-cycle arrest, and apoptosis. An investigator-initiated clinical trial involving four patients showed benefits in three cases. In addition, a subset of cells exhibited senescence and senescence-associated secretory phenotype post–Ara-C treatment, accompanied by several immune checkpoint ligands’ up-regulation and more immune cell infiltration. Combining Ara-C with dual Programmed cell death protein 1 (PD-1) and TIGIT blockade emerged as a promising strategy to disrupt immune evasion by senescent cells, enhancing antitumor responses. These findings highlight Ara-C’s potential as a monotherapy and in synergy with immunotherapy for H3-SCDMG, offering potential strategies for clinical management.
- 18 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (16) , eadu3956
Open AccessAra-C suppresses H3 K27–altered spinal cord diffuse midline glioma growth and enhances immune checkpoint blockade sensitivity
H3 K27–altered spinal cord diffuse midline glioma (H3-SCDMG) poses therapeutic challenges. Analysis of 73 clinical samples revealed heightened proliferation in H3-SCDMG versus wild-type tumors, suggesting therapeutic vulnerabilities. Drug screening identified cytarabine (Ara-C) as highly effective in inhibiting proliferation in H3 K27M cell models, recently established patient-derived cells, and patient-derived xenograft models. Mechanistically, Ara-C can suppress tumor growth through DNA damage, cell-cycle arrest, and apoptosis. An investigator-initiated clinical trial involving four patients showed benefits in three cases. In addition, a subset of cells exhibited senescence and senescence-associated secretory phenotype post–Ara-C treatment, accompanied by several immune checkpoint ligands’ up-regulation and more immune cell infiltration. Combining Ara-C with dual Programmed cell death protein 1 (PD-1) and TIGIT blockade emerged as a promising strategy to disrupt immune evasion by senescent cells, enhancing antitumor responses. These findings highlight Ara-C’s potential as a monotherapy and in synergy with immunotherapy for H3-SCDMG, offering potential strategies for clinical management.
- Open Access
- 1 January 2024
- Published by XMLink in Korean Journal of Radiology
- Vol. 25 (1) , 74-85
Prediction of Venous Trans-Stenotic Pressure Gradient Using Shape Features Derived From Magnetic Resonance Venography in Idiopathic Intracranial Hypertension Patients
Ma C, et al. Korean J Radiol. 2024 Jan;25(1):74-85. https://doi.org/10.3348/kjr.2023.0911
- 1 January 2024
- Published by XMLink in Korean Journal of Radiology
- Vol. 25 (1) , 74-85
Open AccessPrediction of Venous Trans-Stenotic Pressure Gradient Using Shape Features Derived From Magnetic Resonance Venography in Idiopathic Intracranial Hypertension Patients
Ma C, et al. Korean J Radiol. 2024 Jan;25(1):74-85. https://doi.org/10.3348/kjr.2023.0911
- 4 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (716) , eadh4181
Identifying predictors of glioma evolution from longitudinal sequencing
Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A deletion at initial diagnosis preceded tumor necrosis and microvascular proliferation that occur at later stages of IDH-mutant glioma. Ki67 expression at diagnosis was positively correlated with acquiring hypermutation at recurrence in the IDH–wild-type glioma. In all glioma subtypes, MYC gain or MYC- target activation at diagnosis was associated with treatment-induced hypermutation at recurrence. To predict glioma evolution, we constructed CELLO2 (Cancer EvoLution for LOngitudinal data version 2), a machine learning model integrating features at diagnosis to forecast hypermutation and progression after treatment. CELLO2 successfully stratified patients into subgroups with distinct prognoses and identified a high-risk patient group featured by MYC gain with worse post-progression survival, from the low-grade IDH-mutant-noncodel subtype. We then performed chronic temozolomide-induction experiments in glioma cell lines and isogenic patient-derived gliomaspheres and demonstrated that MYC drives temozolomide resistance by promoting hypermutation. Mechanistically, we demonstrated that, by binding to open chromatin and transcriptionally active genomic regions, c-MYC increases the vulnerability of key mismatch repair genes to treatment-induced mutagenesis, thus triggering hypermutation. This study reveals early predictors of cancer evolution under therapy and provides a resource for precision oncology targeting cancer dynamics in diffuse gliomas.
- 4 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (716) , eadh4181
Identifying predictors of glioma evolution from longitudinal sequencing
Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A deletion at initial diagnosis preceded tumor necrosis and microvascular proliferation that occur at later stages of IDH-mutant glioma. Ki67 expression at diagnosis was positively correlated with acquiring hypermutation at recurrence in the IDH–wild-type glioma. In all glioma subtypes, MYC gain or MYC- target activation at diagnosis was associated with treatment-induced hypermutation at recurrence. To predict glioma evolution, we constructed CELLO2 (Cancer EvoLution for LOngitudinal data version 2), a machine learning model integrating features at diagnosis to forecast hypermutation and progression after treatment. CELLO2 successfully stratified patients into subgroups with distinct prognoses and identified a high-risk patient group featured by MYC gain with worse post-progression survival, from the low-grade IDH-mutant-noncodel subtype. We then performed chronic temozolomide-induction experiments in glioma cell lines and isogenic patient-derived gliomaspheres and demonstrated that MYC drives temozolomide resistance by promoting hypermutation. Mechanistically, we demonstrated that, by binding to open chromatin and transcriptionally active genomic regions, c-MYC increases the vulnerability of key mismatch repair genes to treatment-induced mutagenesis, thus triggering hypermutation. This study reveals early predictors of cancer evolution under therapy and provides a resource for precision oncology targeting cancer dynamics in diffuse gliomas.
- Open Access
A Bayesian Multivariate Mixture Model for Spatial Transcriptomics Data
High throughput spatial transcriptomics (HST) is a rapidly emerging class of experimental technologies that allow for profiling gene expression in tissue samples at or near single-cell resolution while retaining the spatial location of each sequencing unit within the tissue sample. Through analyzing HST data, we seek to identify sub-populations within a tissue sample that reflect distinct cell types or states. Existing methods either ignore the spatial heterogeneity in gene expression profiles, fail to account for important statistical features such as skewness, or are heuristic network-based clustering methods that lack the inferential benefits of statistical modeling. To address this gap, we develop SPRUCE: a Bayesian spatial multivariate finite mixture model based on multivariate skew-normal distributions, which is capable of identifying distinct cellular sub-populations in HST data. We further implement a novel combination of Pólya–Gamma data augmentation and spatial random effects to infer spatially correlated mixture component membership probabilities without relying on approximate inference techniques. Via a simulation study, we demonstrate the detrimental inferential effects of ignoring skewness or spatial correlation in HST data. Using publicly available human brain HST data, SPRUCE outperforms existing methods in recovering expertly annotated brain layers. Finally, our application of SPRUCE to human breast cancer HST data indicates that SPRUCE can distinguish distinct cell populations within the tumor microenvironment.
Open AccessA Bayesian Multivariate Mixture Model for Spatial Transcriptomics Data
High throughput spatial transcriptomics (HST) is a rapidly emerging class of experimental technologies that allow for profiling gene expression in tissue samples at or near single-cell resolution while retaining the spatial location of each sequencing unit within the tissue sample. Through analyzing HST data, we seek to identify sub-populations within a tissue sample that reflect distinct cell types or states. Existing methods either ignore the spatial heterogeneity in gene expression profiles, fail to account for important statistical features such as skewness, or are heuristic network-based clustering methods that lack the inferential benefits of statistical modeling. To address this gap, we develop SPRUCE: a Bayesian spatial multivariate finite mixture model based on multivariate skew-normal distributions, which is capable of identifying distinct cellular sub-populations in HST data. We further implement a novel combination of Pólya–Gamma data augmentation and spatial random effects to infer spatially correlated mixture component membership probabilities without relying on approximate inference techniques. Via a simulation study, we demonstrate the detrimental inferential effects of ignoring skewness or spatial correlation in HST data. Using publicly available human brain HST data, SPRUCE outperforms existing methods in recovering expertly annotated brain layers. Finally, our application of SPRUCE to human breast cancer HST data indicates that SPRUCE can distinguish distinct cell populations within the tumor microenvironment.